With Travis Kalanick out as Uber’s chief executive, the company has a chance to improve its treatment of drivers. An option for tipping drivers is a start.
NYS Entity Status
NYS Filing Date
MARCH 19, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - JOHNSON & COMPANY HOME IMPROVEMENT, INC.
AROUND THE WEB
- News Analysis: Tough Task for Next Uber Leader: Mending Fences With Drivers
By KEVIN ROOSE - Thursday Jun 22, 2017
- Sprint, Looking to Get Bigger to Survive, Weighs Deal-Making
By MICHAEL J. de la MERCED - Monday Aug 7, 2017
The company and its backer, SoftBank, have had talks with both Charter and T-Mobile to improve its fortunes as it falls behind rivals.
- Under the Stars and Quilts, With Randalls Island as Her Stage
By GIA KOURLAS - Friday Aug 11, 2017
For her newest performance project, the dance artist Emily Johnson will gather 300 people for an all-night event.
- A Slump in Tech Stocks That Leaves Some Investors Mystified
By LANDON THOMAS Jr. - Monday Jun 12, 2017
Shares of Netflix, Apple and other giant technology companies that have powered a market rally have taken an uncharacteristic pause.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.